FILANA THERAPEUTICS, INC. — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Richard J. Barry (CEO) and Eric J. Schoen (CFO) certified the Q2 2026 10-Q for the period ended June 30, 2026, dated July 29, 2026. Both officers attested that the report contains no material untrue statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are designed and operating effectively. No specific operational, financial, or transactional changes are disclosed in these certification exhibits.
Why this rating
Boilerplate Sarbanes-Oxley certification exhibits with no disclosed operational changes, transactions, or material events affecting the $87M market-cap company.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.